Journal of Affective Disorders
May 7, 2023
Wei Zheng, Yanling Zhou, Chengyu Wang et al.
OBJECTIVES This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression. METHODS The safety, antidepressant, and anti-suicidal effects of multi-infusion ketamine were compared between 19 elderly (≥50 years) and 116 younger (<50 years) adults with depression; all were treated with six...
European Neuropsychopharmacology
May 4, 2023
Stefania Chiappini, Giacomo D’andrea, Sergio De Filippis et al.
48 citations
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal...
The Brown University Psychopharmacology Update
May 3, 2023
symptoms of depression and anxiety and evaluated socio-occupational functioning. Twenty-two participants were randomized to treatment. The infusions were well-tolerated, with no serious adverse events. Most of the findings were suggestive but not statistically significant. Post-infusion scores on the primary outcome decreased more in the ketamine group than in the midazolam group. The greatest...
Life Science
May 1, 2023
Miroslav Adzic, Iva Lukic, Milos Mitic et al.
Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30-50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield...
Journal of Affective Disorders
May 1, 2023
Tuuli M. Hietamies, L. Mcinnes, A. Klise et al.
INTRODUCTION Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions. A rapidly proliferating number of clinics offer KIT for depression and anxiety, using protocols without a strong evidence basis. Controlled comparison of mood and anxiety from real-world KIT clinics, and the stability of outcomes, is lacking....
Experimental and Clinical Psychopharmacology
May 1, 2023
Jesús Herrera-Imbroda
Treatment-resistant depression (TRD) is a major public health problem worldwide. There are currently five strategies for its treatment: optimization, change, combination, augmentation, and somatic therapies. However, many of these therapies are not fully effective, are not accessible, or have a significant number of side effects. Esketamine nasal spray has recently been approved, in combination...
Heliyon
May 1, 2023
Jolien K E Veraart, M. van Westenbrugge, J.E. van Wulfften Palthe et al.
30 citations
Introduction: Ketamine and its S-enantiomer esketamine are novel pharmacotherapeutic options for treatment resistant depression (TRD). There is growing evidence on the efficacy for other psychiatric disorders, including posttraumatic stress disorder (PTSD). It is hypothesized that psychotherapy may further potentiate the effects of (es)ketamine in psychiatric disorders. Methods: Repeated oral...
JAMA Network Open
May 1, 2023
R. Price, M. Wallace, S. Mathew et al.
9 citations
This secondary analysis of a randomized clinical trial examines whether automated self-association training can prolong the antidepressant effect of a single infusion of ketamine beyond 1 month in patients with treatment-resistant depression.
Behavioural Brain Research
May 1, 2023
S. Kantor, Michael Lanigan, Lauren Giggins et al.
11 citations
Wistar-Kyoto (WKY) rats exhibit depression-like characteristics and decreased sensitivity to monoamine-based antidepressants, making them a suitable model of treatment-resistant depression (TRD). Ketamine has emerged recently as a rapidly acting antidepressant with high efficacy in TRD. Our aim was to determine whether subanaesthetic doses of ketamine can correct sleep and electroencephalogram...
Psychological Medicine
April 26, 2023
Abstract: While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression. The objective of this review was to assess quality of reporting AEs in all published clinical trials studying esketamine. It also aimed to compare the...